Ongoing CAR T-cell trials in hematologic malignancies
| Antigen . | Cancers . | Gene transfer . | CAR signaling domain . | Phase/ID . | Sponsor . | Cell type/selection/drug combination . | Reference . |
|---|---|---|---|---|---|---|---|
| CD19 | Pediatric B-cell leukemia and lymphoma | Lentivirus | 4-1BB–CD3ζ | 1/NCT01626495 | CHOP/University of Pennsylvania | 37 | |
| CD19 | CD19+ malignancies | Lentivirus | 4-1BB–CD3ζ | 1/NCT01029366 | University of Pennsylvania | 34 | |
| CD19 | ALL (post–allo-HSCT) | Lentivirus | 4-1BB–CD3ζ | 1/NCT 01551043 | University of Pennsylvania | T cells from donor | |
| CD19 | CLL (randomized to 1 of 2 doses) | Lentivirus | 4-1BB–CD3ζ | II/NCT01747486 | University of Pennsylvania | ||
| CD19 | CLL | Retrovirus/ lentivirus | CD28-CD3ζ; 4-1BB–CD3ζ | 1/2/NCT00466531 | MSKCC/University of Pennsylvania | ||
| CD19 | ALL | CD28-CD3ζ | 1/NCT01044069 | MSKCC | 32 | ||
| CD19 | Auto-HSCT for NHL followed by T-cell infusion | Retrovirus | CD28-CD3ζ | 1/NCT01840566 | MSKCC | ||
| CD19 | Relapsed ALL post–allo-HSCT | Retrovirus | CD28-CD3ζ | 1/NCT01430390 | MSKCC | CD19 CAR-transduced EBV-specific CTLs from donor | |
| CD19 | CLL (residual disease following upfront pentostatin/cyclophosphamide/rituximab) | Retrovirus | CD28-CD3ζ | 1/NCT1416974 | MSKCC | 30 | |
| CD19 | Pediatric relapsed B-cell ALL | Retrovirus | CD28-CD3ζ | 1/NCT01860937 | MSKCC | ||
| CD19 | NHL, CLL | Retrovirus | CD28–4-1BB-CD3ζ and CD28-CD3ζ | 1/NCT01853631 | Baylor College of Medicine | 2 CARs at the same time | |
| CD19 | ALL, CLL, NHL | Retrovirus | CD28-CD3ζ | 1/NCT00586391 | Baylor College of Medicine | Ipilimumab in low-grade disease (2 wk after T cells) | |
| CD19 | ALL, CLL, NHL post–allo-HSCT (prophylaxis or therapy) | Retrovirus | CD28-CD3ζ | 1/2/NCT00840853 | Baylor College of Medicine | CD19 CAR-transduced trivirus-specific CTLs (CMV, EBV, and adenovirus) from donor | 23 |
| CD19 | CLL | Transposon | CD28-CD3ζ | 1/NCT01653717 | MD Anderson Cancer Center | ||
| CD19 | Leukemia/lymphoma post–cord blood HSCT | Transposon | CD28-CD3ζ | 1/NCT01362452 | MD Anderson Cancer Center | ||
| CD19 | B-cell malignancies post–allo-HSCT | Transposon | CD28-CD3ζ | 1/NCT01497184 | MD Anderson Cancer Center | Donor derived | |
| CD19 | B-cell malignancies post–auto-HSCT | Transposon | CD28-CD3ζ | 1/NCT00968760 | MD Anderson Cancer Center | Low- and high-dose cohorts with and without IL-2 | |
| CD19 | Pediatric leukemia and lymphoma | Retrovirus | CD28-CD3ζ | 1/NCT01593696 | National Cancer Institute | ||
| CD19 | CLL, small lymphocytic lymphoma; MCL, follicular lymphoma, large-cell lymphoma | Retrovirus | CD28-CD3ζ | 1/2/NCT00924326 | National Cancer Institute | IL-2 | |
| CD19 | B-cell malignancies relapsed post–allo-HSCT | Retrovirus | CD28-CD3ζ | 1/NCT01087294 | National Cancer Institute | T cells from donor | 29 |
| CD19 | Auto-HSCT for NHL followed by T-cell infusion (day 2 or 3) | Lentivirus | CD3ζ | 1/2/NCT01318317 | City of Hope | TCM-enriched CD8+ T cells | |
| CD19/EGFRt | Auto-HSCT for NHL followed by T-cell infusion (day 2 or 3) | Lentivirus | CD28-CD3ζ | 1/NCT01815749 | City of Hope | TCM-enriched T cells (cetuximab as possible suicide system) | |
| CD19/EGFRt | Pediatric ALL | Lentivirus | CD28-CD3ζ | 1/NCT01683279 | Seattle Children’s Hospital | ||
| CD19 | Relapse/refractory CLL, NHL, or ALL | Lentivirus | CD3ζ | 1/2/NCT01865617 | Fred Hutchinson Cancer Research Center | ||
| CD19/EGFRt | ALL, DLBCL, MCL, NHL, CLL relapsed post–allo-HSCT | Lentivirus | CD28-CD3ζ | 1/2/NCT01475058 | Fred Hutchinson Cancer Research Center | Donor-derived, CMV- or EBV-specific CD62L+ TCM | |
| CD19 | Pediatric ALL post–allo-HSCT | Retrovirus | CD3ζ | 1/2/NCT01195480 | University College, London | CD19 CAR-transduced EBV-specific CTLs from donor; 2nd cohort adds vaccination with irradiated EBV-LCL | |
| CD19 | ALL, CLL, NHL | Retrovirus | CD137-CD3ζ and CD3ζ | 1/2/NCT01864889 | Chinese PLA General Hospital | ||
| CD30 | NHL, HL | Retrovirus | CD28-CD3ζ | 1/NCT01316146 | Baylor College of Medicine | ||
| CD30 | NHL, HL | Retrovirus | CD28-CD3ζ | 1/NCT01192464 | Baylor College of Medicine | CD30 CAR-transduced EBV-specific CTLs | |
| CD30 | Mycosis fungoides/CTCL | Retrovirus | CD28-CD3ζ | 1/NCT01645293 | University of Cologne | 78 | |
| Ig κ light chain | Lymphoma, myeloma, leukemia | Retrovirus | CD28-CD3ζ | 1/NCT00881920 | Baylor College of Medicine | ||
| CD20 | CD20+ leukemia and lymphoma | Retrovirus | 4-1BB–CD3ζ | 1/2/NCT01735604 | Chinese PLA General Hospital | ||
| CD33 | Relapsed/refractory CD33+ AML | Retrovirus | CD137-CD3ζ and CD3ζ | 1/2/NCT01864902 | Chinese PLA General Hospital | ||
| CD138 | Relapsed and/or chemotherapy resistant multiple myeloma | Retrovirus | CD137-CD3ζ and CD3ζ | 1/2/NCT01886976 | Chinese PLA General Hospital | ||
| Lewis-Y | AML, MDS, multiple myeloma | Retrovirus | Anti–Lewis-Y-CD28-CD3ζ | 1/NCT01716364 | Peter MacCullum Cancer Centre, Australia | 41 |
| Antigen . | Cancers . | Gene transfer . | CAR signaling domain . | Phase/ID . | Sponsor . | Cell type/selection/drug combination . | Reference . |
|---|---|---|---|---|---|---|---|
| CD19 | Pediatric B-cell leukemia and lymphoma | Lentivirus | 4-1BB–CD3ζ | 1/NCT01626495 | CHOP/University of Pennsylvania | 37 | |
| CD19 | CD19+ malignancies | Lentivirus | 4-1BB–CD3ζ | 1/NCT01029366 | University of Pennsylvania | 34 | |
| CD19 | ALL (post–allo-HSCT) | Lentivirus | 4-1BB–CD3ζ | 1/NCT 01551043 | University of Pennsylvania | T cells from donor | |
| CD19 | CLL (randomized to 1 of 2 doses) | Lentivirus | 4-1BB–CD3ζ | II/NCT01747486 | University of Pennsylvania | ||
| CD19 | CLL | Retrovirus/ lentivirus | CD28-CD3ζ; 4-1BB–CD3ζ | 1/2/NCT00466531 | MSKCC/University of Pennsylvania | ||
| CD19 | ALL | CD28-CD3ζ | 1/NCT01044069 | MSKCC | 32 | ||
| CD19 | Auto-HSCT for NHL followed by T-cell infusion | Retrovirus | CD28-CD3ζ | 1/NCT01840566 | MSKCC | ||
| CD19 | Relapsed ALL post–allo-HSCT | Retrovirus | CD28-CD3ζ | 1/NCT01430390 | MSKCC | CD19 CAR-transduced EBV-specific CTLs from donor | |
| CD19 | CLL (residual disease following upfront pentostatin/cyclophosphamide/rituximab) | Retrovirus | CD28-CD3ζ | 1/NCT1416974 | MSKCC | 30 | |
| CD19 | Pediatric relapsed B-cell ALL | Retrovirus | CD28-CD3ζ | 1/NCT01860937 | MSKCC | ||
| CD19 | NHL, CLL | Retrovirus | CD28–4-1BB-CD3ζ and CD28-CD3ζ | 1/NCT01853631 | Baylor College of Medicine | 2 CARs at the same time | |
| CD19 | ALL, CLL, NHL | Retrovirus | CD28-CD3ζ | 1/NCT00586391 | Baylor College of Medicine | Ipilimumab in low-grade disease (2 wk after T cells) | |
| CD19 | ALL, CLL, NHL post–allo-HSCT (prophylaxis or therapy) | Retrovirus | CD28-CD3ζ | 1/2/NCT00840853 | Baylor College of Medicine | CD19 CAR-transduced trivirus-specific CTLs (CMV, EBV, and adenovirus) from donor | 23 |
| CD19 | CLL | Transposon | CD28-CD3ζ | 1/NCT01653717 | MD Anderson Cancer Center | ||
| CD19 | Leukemia/lymphoma post–cord blood HSCT | Transposon | CD28-CD3ζ | 1/NCT01362452 | MD Anderson Cancer Center | ||
| CD19 | B-cell malignancies post–allo-HSCT | Transposon | CD28-CD3ζ | 1/NCT01497184 | MD Anderson Cancer Center | Donor derived | |
| CD19 | B-cell malignancies post–auto-HSCT | Transposon | CD28-CD3ζ | 1/NCT00968760 | MD Anderson Cancer Center | Low- and high-dose cohorts with and without IL-2 | |
| CD19 | Pediatric leukemia and lymphoma | Retrovirus | CD28-CD3ζ | 1/NCT01593696 | National Cancer Institute | ||
| CD19 | CLL, small lymphocytic lymphoma; MCL, follicular lymphoma, large-cell lymphoma | Retrovirus | CD28-CD3ζ | 1/2/NCT00924326 | National Cancer Institute | IL-2 | |
| CD19 | B-cell malignancies relapsed post–allo-HSCT | Retrovirus | CD28-CD3ζ | 1/NCT01087294 | National Cancer Institute | T cells from donor | 29 |
| CD19 | Auto-HSCT for NHL followed by T-cell infusion (day 2 or 3) | Lentivirus | CD3ζ | 1/2/NCT01318317 | City of Hope | TCM-enriched CD8+ T cells | |
| CD19/EGFRt | Auto-HSCT for NHL followed by T-cell infusion (day 2 or 3) | Lentivirus | CD28-CD3ζ | 1/NCT01815749 | City of Hope | TCM-enriched T cells (cetuximab as possible suicide system) | |
| CD19/EGFRt | Pediatric ALL | Lentivirus | CD28-CD3ζ | 1/NCT01683279 | Seattle Children’s Hospital | ||
| CD19 | Relapse/refractory CLL, NHL, or ALL | Lentivirus | CD3ζ | 1/2/NCT01865617 | Fred Hutchinson Cancer Research Center | ||
| CD19/EGFRt | ALL, DLBCL, MCL, NHL, CLL relapsed post–allo-HSCT | Lentivirus | CD28-CD3ζ | 1/2/NCT01475058 | Fred Hutchinson Cancer Research Center | Donor-derived, CMV- or EBV-specific CD62L+ TCM | |
| CD19 | Pediatric ALL post–allo-HSCT | Retrovirus | CD3ζ | 1/2/NCT01195480 | University College, London | CD19 CAR-transduced EBV-specific CTLs from donor; 2nd cohort adds vaccination with irradiated EBV-LCL | |
| CD19 | ALL, CLL, NHL | Retrovirus | CD137-CD3ζ and CD3ζ | 1/2/NCT01864889 | Chinese PLA General Hospital | ||
| CD30 | NHL, HL | Retrovirus | CD28-CD3ζ | 1/NCT01316146 | Baylor College of Medicine | ||
| CD30 | NHL, HL | Retrovirus | CD28-CD3ζ | 1/NCT01192464 | Baylor College of Medicine | CD30 CAR-transduced EBV-specific CTLs | |
| CD30 | Mycosis fungoides/CTCL | Retrovirus | CD28-CD3ζ | 1/NCT01645293 | University of Cologne | 78 | |
| Ig κ light chain | Lymphoma, myeloma, leukemia | Retrovirus | CD28-CD3ζ | 1/NCT00881920 | Baylor College of Medicine | ||
| CD20 | CD20+ leukemia and lymphoma | Retrovirus | 4-1BB–CD3ζ | 1/2/NCT01735604 | Chinese PLA General Hospital | ||
| CD33 | Relapsed/refractory CD33+ AML | Retrovirus | CD137-CD3ζ and CD3ζ | 1/2/NCT01864902 | Chinese PLA General Hospital | ||
| CD138 | Relapsed and/or chemotherapy resistant multiple myeloma | Retrovirus | CD137-CD3ζ and CD3ζ | 1/2/NCT01886976 | Chinese PLA General Hospital | ||
| Lewis-Y | AML, MDS, multiple myeloma | Retrovirus | Anti–Lewis-Y-CD28-CD3ζ | 1/NCT01716364 | Peter MacCullum Cancer Centre, Australia | 41 |
Allo-HSCT, allogeneic hematopoietic stem cell transplantation; auto-HSCT, autologous hematopoietic stem cell transplantation; CHOP, Children’s Hospital of Philadelphia; CMV, cytomegalovirus; CTCL, cutaneous T-cell lymphoma; CTLs, cytotoxic T lymphocytes; DLBCL, diffuse large B-cell lymphoma; EBV, Epstein-Barr virus; HL, Hodgkin lymphoma; Ig, immunoglobulin; MCL, mantle cell lymphoma; MDS, myelodysplastic syndrome; NHL, non-Hodgkin lymphoma.